----
Current ValuationThe current P/E ratio is -3.03, above the reasonable range, cheaper than 0.38% of the time in the past 1 years, and the industry ranks 26/38, the industry Median -0.84.
-3.03xP/E
$4.30Stock price
$-1.42Earnings per share
-3.03xP/E
Stock price$4.30Earnings per share$-1.42
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -16.64x
- Typical range
- -27.58x–-9.84x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
012243648
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
HTFLUSHeartFlow | -36.54x | 74.45% | $4.33B |
SDGRUSSchrodinger | -37.56x | 13.66% | $2.04B |
CERTUSCertara | -20.36x | 2,116.80% | $1.39B |
TDOCUSTeladoc | -5.91x | 22.88% | $1.05B |
MDRXUSVeradigm | -- | -- | $866.76M |
SOPHUSSophia Genetics SA | -7.80x | 19.83% | $630.80M |
EVHUSEvolent Health | -0.89x | 84.41% | $456.76M |
CTEVUSClaritev | -1.48x | 12.62% | $417.92M |
AMWLUSAmerican Well | -2.77x | 57.74% | $216.01M |
DHUSDefinitive Healthcare | -0.84x | 28.60% | $141.94M |
HCATUSHealth Catalyst | -0.50x | 4.22% | $133.20M |
LFMDUSLifeMD | -43.63x | 195.82% | $126.77M |
DRIOUSDarioHealth | -8.12x | 62.43% | $56.80M |
RNLXYUSRENALYTIX PLC SPON ADS EACH REP 50 ORD (POST SPLIT) | -2.06x | -- | $41.06M |
ITOCUSiTonic | -3.34x | -- | $29.74M |
ONMDUSOneMedNet | -3.03x | -- | $25.49M |
AIFFUSFirefly Neuroscience | -1.98x | -- | $18.67M |
BFRGUSBullfrog AI | -2.00x | 41.27% | $11.98M |
HCTIUSHealthcare Triangle | -0.43x | 93.28% | $7.24M |
ACONUSAclarion | -0.73x | 65.17% | $6.74M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
